SEARCH

SEARCH BY CITATION

References

  • 1
    McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 151921.
  • 2
    Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 24205.
  • 3
    Abraham N, Hlatky M, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 2010; 122: 261933.
  • 4
    Hulot J, Collet J, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. JACC 2010; 56: 134143.
  • 5
    Greenland S, Lash TL, Rothman KJ. Concepts of interaction. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008; 7186.
  • 6
    Pedersen CB. The Danish civil registration system. Scand J Public Health 2011; 39(7 suppl): 225.
  • 7
    Schmidt M, Maeng M, Jakobsen CJ, et al. Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology 2010; 2: 13744.
  • 8
    Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 4458.
  • 9
    Available drugs and package sizes on the Danish drug market. Available at: http://www.lmk.dk. Accessed November 1, 2010.
  • 10
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl 3): 2736.
  • 11
    Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 2638.
  • 12
    Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011; 39(7 Suppl): 2629.
  • 13
    Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 234451.
  • 14
    Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82: 1193202.
  • 15
    Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 125163.
  • 16
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 91520.
  • 17
    Kwok C, Loke Y. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 81023.
  • 18
    Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 262441.
  • 19
    Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 25660.
  • 20
    Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 2010; 125: e51e54.
  • 21
    Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 7149.
  • 22
    Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. J Am Coll Cardiol 2009; 54: 11491153.
  • 23
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol 2010; 56: 5329.
  • 24
    Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e15.
  • 25
    Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. K Clin Pharmacol 2008; 48: 475484.
  • 26
    O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989997.
  • 27
    Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 7138.
  • 28
    Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 93744.
  • 29
    Rassen J, Choudhry N, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 23229.
  • 30
    Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 70410.
  • 31
    van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010; 105: 24306. quiz 2437.
  • 32
    Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010; 153: 37886.
  • 33
    Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 33745.
  • 34
    Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 36375.
  • 35
    Valkhoff VE, t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011; 33: 7788.
  • 36
    Disney BR, Watson RD, Blann AD, Lip GY, Anderson MR. Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction. Aliment Pharmacol Ther 2011; 33: 75867.
  • 37
    Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011; 107: 8718.
  • 38
    Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Eng J Med 2010; 363: 190917.
  • 39
    Dunn SP, Macaulay TE, Brennan DM. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial (abstr). Circulation 2009; 118: S815.
  • 40
    Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45(10 Suppl. 2): S13142.
  • 41
    Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005; 162: 101623.
  • 42
    Stürmer T, Jonsson Funk M, Poole C, Brookhart MA. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology 2011; 22: 298301.
  • 43
    Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 12430.
  • 44
    Rothman KJ, Greenland S, Lash TL. Validity in epidemiologic studies. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008; 1379.